- Home
- SURG vs IKNA Comparison
SURG vs IKNA Comparison
Compare SURG & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SURG
- IKNA
- Stock Information
- Founded
- SURG 2006
- IKNA 2016
- Country
- SURG United States
- IKNA United States
- Employees
- SURG N/A
- IKNA N/A
- Industry
- SURG Advertising
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- SURG Consumer Discretionary
- IKNA Health Care
- Exchange
- SURG Nasdaq
- IKNA Nasdaq
- Market Cap
- SURG 64.1M
- IKNA 63.7M
- IPO Year
- SURG N/A
- IKNA 2021
- Fundamental
- Price
- SURG $2.94
- IKNA $1.43
- Analyst Decision
- SURG Strong Buy
- IKNA Buy
- Analyst Count
- SURG 1
- IKNA 2
- Target Price
- SURG $9.00
- IKNA $13.50
- AVG Volume (30 Days)
- SURG 68.8K
- IKNA 434.6K
- Earning Date
- SURG 08-12-2025
- IKNA 07-24-2025
- Dividend Yield
- SURG N/A
- IKNA N/A
- EPS Growth
- SURG N/A
- IKNA N/A
- EPS
- SURG N/A
- IKNA N/A
- Revenue
- SURG $40,029,467.00
- IKNA N/A
- Revenue This Year
- SURG $57.76
- IKNA N/A
- Revenue Next Year
- SURG $112.61
- IKNA N/A
- P/E Ratio
- SURG N/A
- IKNA N/A
- Revenue Growth
- SURG N/A
- IKNA N/A
- 52 Week Low
- SURG $1.05
- IKNA $0.97
- 52 Week High
- SURG $3.47
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- SURG 46.76
- IKNA 59.83
- Support Level
- SURG $2.86
- IKNA $1.20
- Resistance Level
- SURG $3.13
- IKNA $1.42
- Average True Range (ATR)
- SURG 0.15
- IKNA 0.08
- MACD
- SURG -0.02
- IKNA 0.00
- Stochastic Oscillator
- SURG 13.56
- IKNA 82.26
About SURG SurgePays Inc.
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.